ES3005632T3 - Abca1-inducing compounds for use in treating kidney disorders - Google Patents
Abca1-inducing compounds for use in treating kidney disorders Download PDFInfo
- Publication number
- ES3005632T3 ES3005632T3 ES19749657T ES19749657T ES3005632T3 ES 3005632 T3 ES3005632 T3 ES 3005632T3 ES 19749657 T ES19749657 T ES 19749657T ES 19749657 T ES19749657 T ES 19749657T ES 3005632 T3 ES3005632 T3 ES 3005632T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- use according
- alkyl
- group
- comp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18185871 | 2018-07-26 | ||
| PCT/EP2019/070251 WO2020021097A1 (en) | 2018-07-26 | 2019-07-26 | Compounds for use in treating kidney disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3005632T3 true ES3005632T3 (en) | 2025-03-14 |
Family
ID=63077813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19749657T Active ES3005632T3 (en) | 2018-07-26 | 2019-07-26 | Abca1-inducing compounds for use in treating kidney disorders |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20200085810A1 (enExample) |
| EP (2) | EP4537901A3 (enExample) |
| JP (2) | JP7478133B2 (enExample) |
| KR (1) | KR102860768B1 (enExample) |
| CN (2) | CN112469442B (enExample) |
| AU (1) | AU2019310919B2 (enExample) |
| CA (1) | CA3104793A1 (enExample) |
| ES (1) | ES3005632T3 (enExample) |
| IL (1) | IL280368B2 (enExample) |
| MX (1) | MX2021000976A (enExample) |
| PL (1) | PL3826679T3 (enExample) |
| TW (1) | TWI891608B (enExample) |
| WO (1) | WO2020021097A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200085810A1 (en) * | 2018-07-26 | 2020-03-19 | Hoffmann-La Roche Inc. | Compounds for use in treating kidney disorders |
| WO2022006277A1 (en) * | 2020-07-01 | 2022-01-06 | Angion Biomedica Corp. | Methods for treatment of fibrotic kidney diseases |
| US11814354B2 (en) | 2021-09-08 | 2023-11-14 | River 3 Renal Corp. | Solid forms |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1270846B (it) | 1993-05-10 | 1997-05-13 | Alfa Wassermann Spa | Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della nefropatia diabetica. |
| US7030146B2 (en) | 1996-09-10 | 2006-04-18 | University Of South Carolina | Methods for treating diabetic neuropathy |
| MXPA06010815A (es) | 2004-03-26 | 2006-12-15 | Hoffmann La Roche | Tetrahidrocarbazoles y derivados de los mismos. |
| EP1756096B1 (en) | 2004-05-03 | 2009-08-12 | F.Hoffmann-La Roche Ag | Indolyl derivatives as liver-x-receptor modulators |
| UA107088C2 (xx) * | 2009-09-11 | 2014-11-25 | 5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину | |
| AR079022A1 (es) * | 2009-11-02 | 2011-12-21 | Sanofi Aventis | Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion |
| WO2012031817A1 (en) | 2010-09-09 | 2012-03-15 | F. Hoffmann-La Roche Ag | Determination of abca1 protein levels in cells |
| AR085013A1 (es) * | 2011-01-26 | 2013-08-07 | Sanofi Aventis | Derivados de acido 3-heteroaroilamino-propionico sustituidos y su uso como sustancias farmaceuticas |
| US9321727B2 (en) * | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| BR112014005634A2 (pt) | 2011-09-12 | 2017-03-28 | Hoffmann La Roche | hidrazidas de 3-piridina ácido carboxílico como agentes de aumento de colesterol hdl |
| WO2014180741A1 (en) * | 2013-05-06 | 2014-11-13 | F. Hoffmann-La Roche Ag | Methods of identifying modulators of osbpl7 and the use of such modulators for treatment of diseases associated with osbpl7 |
| KR20160030206A (ko) * | 2013-07-10 | 2016-03-16 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 사구체 질환을 치료하는데 사용하기 위한 로스마피모드 |
| US20200085810A1 (en) * | 2018-07-26 | 2020-03-19 | Hoffmann-La Roche Inc. | Compounds for use in treating kidney disorders |
-
2019
- 2019-07-25 US US16/522,116 patent/US20200085810A1/en not_active Abandoned
- 2019-07-26 CN CN201980048869.4A patent/CN112469442B/zh active Active
- 2019-07-26 CN CN202311697211.0A patent/CN117736141A/zh active Pending
- 2019-07-26 EP EP24213767.7A patent/EP4537901A3/en active Pending
- 2019-07-26 KR KR1020217002388A patent/KR102860768B1/ko active Active
- 2019-07-26 JP JP2021504186A patent/JP7478133B2/ja active Active
- 2019-07-26 IL IL280368A patent/IL280368B2/en unknown
- 2019-07-26 TW TW108126640A patent/TWI891608B/zh active
- 2019-07-26 PL PL19749657.3T patent/PL3826679T3/pl unknown
- 2019-07-26 MX MX2021000976A patent/MX2021000976A/es unknown
- 2019-07-26 AU AU2019310919A patent/AU2019310919B2/en active Active
- 2019-07-26 EP EP19749657.3A patent/EP3826679B1/en active Active
- 2019-07-26 CA CA3104793A patent/CA3104793A1/en active Pending
- 2019-07-26 ES ES19749657T patent/ES3005632T3/es active Active
- 2019-07-26 WO PCT/EP2019/070251 patent/WO2020021097A1/en not_active Ceased
-
2021
- 2021-03-19 US US17/206,955 patent/US20210275514A1/en not_active Abandoned
-
2024
- 2024-03-27 US US18/618,124 patent/US20240325372A1/en active Pending
- 2024-04-19 JP JP2024068208A patent/JP2024096989A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PL3826679T3 (pl) | 2025-03-10 |
| JP7478133B2 (ja) | 2024-05-02 |
| KR20210038884A (ko) | 2021-04-08 |
| AU2019310919B2 (en) | 2025-04-03 |
| IL280368B1 (en) | 2023-10-01 |
| CA3104793A1 (en) | 2020-01-30 |
| JP2024096989A (ja) | 2024-07-17 |
| EP3826679B1 (en) | 2024-11-27 |
| EP4537901A2 (en) | 2025-04-16 |
| US20240325372A1 (en) | 2024-10-03 |
| TW202019486A (zh) | 2020-06-01 |
| JP2021531308A (ja) | 2021-11-18 |
| KR102860768B1 (ko) | 2025-09-17 |
| EP4537901A3 (en) | 2025-05-21 |
| AU2019310919A1 (en) | 2021-01-07 |
| US20200085810A1 (en) | 2020-03-19 |
| TWI891608B (zh) | 2025-08-01 |
| WO2020021097A1 (en) | 2020-01-30 |
| IL280368A (en) | 2021-03-25 |
| US20210275514A1 (en) | 2021-09-09 |
| IL280368B2 (en) | 2024-02-01 |
| EP3826679C0 (en) | 2024-11-27 |
| EP3826679A1 (en) | 2021-06-02 |
| CN112469442A (zh) | 2021-03-09 |
| CN117736141A (zh) | 2024-03-22 |
| CN112469442B (zh) | 2024-04-09 |
| MX2021000976A (es) | 2021-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240325372A1 (en) | Compounds for use in treating kidney disorders | |
| JP7098214B2 (ja) | 非アルコール性脂肪性肝炎（ＮＡＳＨ）の処置のためのｓＧＣ刺激物質の使用 | |
| RS54492B1 (sr) | Kinazni inhibitor koji reguliše signalni put apoptoze | |
| RS51807B (sr) | Kombinacije za lečenje bolesti koje obuhvataju ćelijsku proliferaciju | |
| WO2019173482A1 (en) | 4-aminoquinoline compounds for the treatment of angiogenesis | |
| AU2009259839A1 (en) | Compositions for the treatment of fibrotic diseases or conditions | |
| WO2012080497A2 (en) | Methods of treatment and prevention of eye diseases | |
| JP2023526055A (ja) | 前立腺癌を治療する方法 | |
| CN115484956A (zh) | 使用ulk1/2抑制剂的单一疗法和联合疗法 | |
| JP7247106B2 (ja) | 内臓痛の治療のための化合物および方法 | |
| US20240279201A1 (en) | Dual wnt signaling pathway inhibitors and ampk activators for treatments of disease | |
| KR102633249B1 (ko) | 조합 치료를 위한 약학 조성물 | |
| JP2021523135A (ja) | 選択的なＮｏｘ阻害活性を有する新規のスルホンアミド誘導体 | |
| HK40102350A (zh) | 用於治疗肾脏疾患的化合物 | |
| HK40040900B (zh) | 用於治疗肾脏疾患的化合物 | |
| HK40040900A (en) | Compounds for use in treating kidney disorders | |
| WO2018157244A1 (en) | Granzyme b inhibitor compositions and methods for the prevention and/or treatment of skin blistering and/or peeling | |
| US9750728B2 (en) | Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway | |
| CN119451944A (zh) | Prep结合配体 | |
| CN119278042A (zh) | 用于血栓性或血栓栓塞性病症中血栓的选择性溶解的糜蛋白酶抑制剂 | |
| Arts | P. ten Holte¹ ()· K. Van Emelen¹· M. Janicot². PC Fong³· JS de Bono³. J. Arts² ¹Dept. of Medicinal Chemistry, Johnson & Johnson Pharmaceutical Research & Development, Division of Janssen Pharmaceutica NV, 2340 Beerse, Belgium | |
| HK40001613B (en) | Use of stimulators of soluble guanylate cyclase for the treatment of nonalcoholic steatohepatitis (nash) |